TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39245360

Group type: EXPERIMENTAL
Intervention: Cemiplimab (3 mg/kg intravenously every 2 weeks) for groups 1 and 2
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Cemiplimab (350 mg intravenously every 3 weeks) for groups 3 and 6
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Serious treatment-emergent adverse events (grade ≥3) for groups 1-3
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Serious treatment-emergent adverse events (grade ≥3) for group 6
Number of subjects: 193
Study: 39245584

Group type: EXPERIMENTAL
Intervention: Pneumococcal Polysaccharide vaccine (PPSV23)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Typhoid Vi Polysaccharide vaccine (Typhim Vi)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 39245679

Group type: EXPERIMENTAL
Intervention: Nutritional support (specifics not provided)
Number of subjects: 238
Study: 39245687

Group type: EXPERIMENTAL
Intervention: Multispectral optoacoustic tomography (MSOT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Muscle magnetic resonance imaging (MRI)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 10

Group type: COMPARATOR
Intervention: Spirometry
Number of subjects: 10

Group type: COMPARATOR
Intervention: Muscle testing
Number of subjects: 10

Group type: COMPARATOR
Intervention: Quality of life scores
Number of subjects: 10
Study: 39245861

Group type: EXPERIMENTAL
Intervention: Patients with ACoA collaterals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collateral circulation patency in unilateral ICA occlusion
Number of subjects: 0
Study: 39245873

Group type: EXPERIMENTAL
Intervention: ATTR-CM diagnosed using cardiac scintigraphy
Number of subjects: 315
Study: 39245876

Group type: EXPERIMENTAL
Intervention: Line-field confocal optical coherence tomography (LC-OCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reflectance confocal microscopy (RCM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both imaging techniques (RCM and LC-OCT)
Number of subjects: 0
Study: 39245937

Group type: EXPERIMENTAL
Intervention: CABA-201 (fully human, 4-1BBz anti-CD19-CAR T cell therapy)
Number of subjects: 1
Study: 39246594

Group type: EXPERIMENTAL
Intervention: Exercise intervention (specific type not detailed)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group - usual care
Number of subjects: 90
Study: 39246736

Group type: EXPERIMENTAL
Intervention: Interpersonal violence (including child sexual abuse, physical violence, domestic violence, sexual assault)
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Domestic violence
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Medication for opioid use disorder
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Mental health counseling
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Mental health medication
Number of subjects: 733
Study: 39246931

Group type: EXPERIMENTAL
Intervention: 5% lifitegrast ophthalmic solution
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (vehicle solution)
Number of subjects: 32
Study: 39247158

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle fatigue protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 39247614

Group type: EXPERIMENTAL
Intervention: Box breathing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness-based breathing exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Everyday life (control)
Number of subjects: 0
Study: 39247678

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 39247686

Group type: EXPERIMENTAL
Intervention: Bamlanivimab 700 mg mAb therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 39247962

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Behavioral Weight Loss (BWL)
Number of subjects: 90
Study: 39247971

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (angiography)
Number of subjects: 30
Study: 39248107

Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg) and Minocycline (100 mg) - dual therapy for 12 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Minocycline (100 mg) or Lovastatin (40 mg) - monotherapy for 8 weeks
Number of subjects: 19
Study: 39248112

Group type: EXPERIMENTAL
Intervention: Pre-obesity group 1 (defined by waist circumference > 96 cm)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pre-obesity group 2 (defined by BMI > 26.5 kg/m2)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-obese group 1
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-obese group 2
Number of subjects: 36
Study: 39248124

Group type: EXPERIMENTAL
Intervention: Beach tennis training (12 weeks, 2 sessions per week, 45-60 minutes each)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 42
Study: 39248170

Group type: EXPERIMENTAL
Intervention: Self-screening for AF with continuous ECG for 3-7 days using ECG247 device.
Number of subjects: 35000

Group type: EXPERIMENTAL
Intervention: Guideline-recommended therapy initiated if AF is detected.
Number of subjects: 35000

Group type: EXPERIMENTAL
Intervention: Follow-up for 5 years through national health registries.
Number of subjects: 35000
Study: 39248249

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 2910

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 2910
Study: 39248270

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Alendronic acid
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 150
Study: 39248314

Group type: EXPERIMENTAL
Intervention: Mazzaferro's Metroticket 2.0 model for survival prediction
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Mazzaferro's Metroticket 2.0 model
Number of subjects: 428
Study: 39248309

Group type: EXPERIMENTAL
Intervention: Depemokimab (100 mg subcutaneously at weeks 0 and 26)
Number of subjects: 762

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Depemokimab
Number of subjects: 762

Group type: COMPARATOR
Intervention: Depemokimab and Placebo
Number of subjects: 762
Study: 39248631

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39248780

Group type: EXPERIMENTAL
Intervention: Belzutifan
Number of subjects: 746

Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 746
Study: 39249590

Group type: EXPERIMENTAL
Intervention: Magaldrate (800 mg) with sodium alginate (500 mg), sodium bicarbonate (267 mg), and simethicone (120 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Magaldrate (800 mg)
Number of subjects: 10
Study: 39249591

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg subcutaneously every two weeks
Number of subjects: 0
Study: 39249605

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with cisplatin-based chemoradiotherapy and pembrolizumab (200 mg, IV every 3 weeks for 18 cycles)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with cisplatin-based chemoradiotherapy and pembrolizumab
Number of subjects: 25
Study: 39250131

Group type: EXPERIMENTAL
Intervention: Nurse-supported self-directed cognitive behavioral therapy for insomnia (CBTi) with six weekly phone calls and assigned treatment manual readings.
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Nurse-supported self-directed cognitive behavioral therapy for insomnia (CBTi)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 178
Study: 39250138

Group type: EXPERIMENTAL
Intervention: JNJ-18038683
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 39250153

Group type: EXPERIMENTAL
Intervention: Chatbot intervention group (pretest genetics education chat)
Number of subjects: 3073

Group type: COMPARATOR
Intervention: Enhanced SOC control group (pretest genetic counseling appointment)
Number of subjects: 3073
Study: 39250155

Group type: EXPERIMENTAL
Intervention: Difficult Error Management Training (EMT)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Easy Error Management Training (EMT)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Error Avoidance Training (EAT) control
Number of subjects: 212
Study: 39250182

Group type: EXPERIMENTAL
Intervention: Email delivery of supportive messages for 6 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: SMS text messaging delivery of supportive messages for 6 weeks
Number of subjects: 66
Study: 39250213

Group type: EXPERIMENTAL
Intervention: Enhanced WeChat mini program
Number of subjects: 247

Group type: COMPARATOR
Intervention: Standard WeChat mini program
Number of subjects: 247
Study: 39250216

Group type: EXPERIMENTAL
Intervention: CTH dashboards
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 62
Study: 39250243

Group type: EXPERIMENTAL
Intervention: Adaptive preventive interventions
Number of subjects: 30
Study: 39250283

Group type: EXPERIMENTAL
Intervention: HRV biofeedback training (8 sessions with physiological monitoring)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (physiological monitoring only)
Number of subjects: 30
Study: 39250326

Group type: EXPERIMENTAL
Intervention: GSK3858279 (monoclonal antibody against CCL17)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (0.9% w/v NaCl)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: GSK3858279
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 39250328

Group type: EXPERIMENTAL
Intervention: Phantom Motor Execution (PME)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Phantom Motor Imagery (PMI)
Number of subjects: 81
Study: 39250514

Group type: EXPERIMENTAL
Intervention: Self-monitoring blood pressure system (BP monitor and mobile phone program)
Number of subjects: 949

Group type: COMPARATOR
Intervention: Control group (no self-monitoring BP system)
Number of subjects: 949
Study: 39250515

Group type: EXPERIMENTAL
Intervention: Resmetirom 80 mg
Number of subjects: 966

Group type: EXPERIMENTAL
Intervention: Resmetirom 100 mg
Number of subjects: 966

Group type: EXPERIMENTAL
Intervention: Resmetirom (80 mg and 100 mg pooled)
Number of subjects: 966

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 966
Study: 39250617

Group type: EXPERIMENTAL
Intervention: Systemic immunosuppression
Number of subjects: 35

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 35
Study: 39250646

Group type: EXPERIMENTAL
Intervention: Peer delivery of oral-fluid HIVST, STISS, and PrEP refills
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) with quarterly in-clinic HIV testing and PrEP refills
Number of subjects: 82
Study: 39250643

Group type: EXPERIMENTAL
Intervention: PrEP stigma
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Anticipated HIV stigma
Number of subjects: 235
Study: 39250647

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) via internet platforms, mailed to participants, with follow-up after 4 months.
Number of subjects: 2195

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) via dating platforms.
Number of subjects: 2195
Study: 39250651

Group type: EXPERIMENTAL
Intervention: DTG + FTC/TAF
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: DTG + FTC/TDF
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: EFV/FTC/TDF
Number of subjects: 643

Group type: COMPARATOR
Intervention: DTG + FTC/TAF, DTG + FTC/TDF, EFV/FTC/TDF
Number of subjects: 643
Study: 39250708

Group type: EXPERIMENTAL
Intervention: Subcutaneous decitabine at 0.3 mg/kg per day for 10 days
Number of subjects: 21
Study: 39250723

Group type: EXPERIMENTAL
Intervention: MOG-AR score developed from the cohort
Number of subjects: 188
Study: 39250750

Group type: EXPERIMENTAL
Intervention: Behavioral Symptoms Score (BSS) at diagnosis
Number of subjects: 3555

Group type: EXPERIMENTAL
Intervention: Behavioral Symptoms Score (BSS) at four years post-diagnosis
Number of subjects: 3555

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 3555

Group type: EXPERIMENTAL
Intervention: Previous psychiatric disorders
Number of subjects: 3555

Group type: EXPERIMENTAL
Intervention: Behavioral Symptoms Score (BSS)
Number of subjects: 3555

Group type: EXPERIMENTAL
Intervention: Genetic risk score
Number of subjects: 3555

Group type: EXPERIMENTAL
Intervention: Model validation
Number of subjects: 3555
Study: 39250787

Group type: EXPERIMENTAL
Intervention: Meds@HOME intervention
Number of subjects: 456

Group type: COMPARATOR
Intervention: Control group (not trialing Meds@HOME)
Number of subjects: 456
Study: 39250792

Group type: EXPERIMENTAL
Intervention: Single-port robotic right colectomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Multiport right colectomy
Number of subjects: 30
Study: 39250887

Group type: EXPERIMENTAL
Intervention: Normobaric hyperoxia (NBO) combined with endovascular treatment (EVT), administered with mask oxygen therapy of 10 L/min.
Number of subjects: 284

Group type: COMPARATOR
Intervention: Sham NBO (1 L/min) combined with endovascular treatment (EVT).
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: NBO combined with EVT
Number of subjects: 284
Study: 39250922

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor plus standard-of-care
Number of subjects: 575

Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 575
Study: 39251131

Group type: EXPERIMENTAL
Intervention: Extensive ablation (PVI-plus group)
Number of subjects: 497

Group type: COMPARATOR
Intervention: PVI-alone (PVI-alone group)
Number of subjects: 497
Study: 39251349

Group type: EXPERIMENTAL
Intervention: Niraparib (300 mg once daily in continuous 28-day cycles)
Number of subjects: 20
Study: 39251366

Group type: EXPERIMENTAL
Intervention: TICK-B (colouring book) and TKTX cream (topical anaesthetic)
Number of subjects: 176

Group type: COMPARATOR
Intervention: TKTX cream (topical anaesthetic)
Number of subjects: 176

Group type: COMPARATOR
Intervention: TICK-B (colouring book)
Number of subjects: 176
Study: 39251447

Group type: EXPERIMENTAL
Intervention: Family Meals on Prescription (FMP) combined with lifestyle treatment
Number of subjects: 89

Group type: COMPARATOR
Intervention: Lifestyle treatment alone (Control)
Number of subjects: 89
Study: 39251486

Group type: EXPERIMENTAL
Intervention: Postintensive care syndrome (PICS) follow-up
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Follow-up over 12 months
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Physical HRQoL scores
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Mental HRQoL scores
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Shorter ICU stay, better functionality, lower scores for fatigue/dyspnea and pain
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Lower scores for anxiety, depression, and PTSD
Number of subjects: 142
Study: 39251561

Group type: COMPARATOR
Intervention: Gatralimab administered via subcutaneous (SC) and intravenous (IV) routes, with doses of 1, 3.5, and 12 mg IV and 12, 36, and 60 mg SC.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gatralimab SC (36, 48, or 60 mg) with different comedications.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methylprednisolone and antihistamine comedications.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-term safety study (NCT02313285).
Number of subjects: 0
Study: 39251616

Group type: EXPERIMENTAL
Intervention: Lower volume administration and higher vasoactive support (postoperative hemodynamic management)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Fluid intake
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Fluid balance
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Norepinephrine administration
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Fluid output
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Blood loss
Number of subjects: 265
Study: 39251643

Group type: EXPERIMENTAL
Intervention: Boxing group (BG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Scapular stabilization group (SSG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60
Study: 39251831

Group type: EXPERIMENTAL
Intervention: Active tVNS (n=63)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Sham tVNS (n=68)
Number of subjects: 131
Study: 39251903

Group type: EXPERIMENTAL
Intervention: Abdominal obesity (WC ≥ 102 cm for men and ≥ 88 cm for women)
Number of subjects: 2806

Group type: COMPARATOR
Intervention: Normal waist circumference (not specified)
Number of subjects: 2806
Study: 39251972

Group type: EXPERIMENTAL
Intervention: Interactive online training modules
Number of subjects: 82
Study: 39251997

Group type: EXPERIMENTAL
Intervention: Short-term indoor PM exposure
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Mid-term indoor PM exposure
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Long-term indoor PM exposure
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Short-term estimated PM exposure
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Mid-term estimated PM exposure
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Long-term estimated PM exposure
Number of subjects: 95
Study: 39252005

Group type: EXPERIMENTAL
Intervention: Home-based contact management intervention
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Task-shared intervention between health extension workers and facility-based TB focal persons
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Community awareness initiatives
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Decentralization of TPT
Number of subjects: 60
Study: 39252007

Group type: EXPERIMENTAL
Intervention: S. aureus isolates from clinical infection among neonates
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: S. aureus associated with clinical infection
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Oropharyngeal S. aureus colonization
Number of subjects: 132
Study: 39252018

Group type: EXPERIMENTAL
Intervention: Medication for opioid use disorder (MOUD)
Number of subjects: 229
Study: 39252084

Group type: EXPERIMENTAL
Intervention: PLACES intervention (n=82)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Care as usual (control group, n=82)
Number of subjects: 164
Study: 39252106

Group type: EXPERIMENTAL
Intervention: Outpatient care (day-surgery)
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Conventional inpatient care (overnight hospitalization)
Number of subjects: 1400
Study: 39252179

Group type: EXPERIMENTAL
Intervention: Potassium binders (sodium polystyrene sulfonate, calcium polystyrene sulfonate, sodium zirconium cyclosilicate)
Number of subjects: 600
Study: 39252484

Group type: EXPERIMENTAL
Intervention: Gaze-contingent music reward therapy (GC-MRT)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 81
Study: 39252529

Group type: EXPERIMENTAL
Intervention: Intravenous idursulfase and intrathecal idursulfase-IT
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intrathecal idursulfase-IT
Number of subjects: 7

Group type: COMPARATOR
Intervention: No idursulfase-IT
Number of subjects: 7
Study: 39252547

Group type: EXPERIMENTAL
Intervention: eIMPACT intervention (internet cognitive-behavioral therapy [CBT], telephonic CBT, and select antidepressant medications)
Number of subjects: 216

Group type: COMPARATOR
Intervention: usual primary care
Number of subjects: 216
Study: 39252591

Group type: EXPERIMENTAL
Intervention: Commissural alignment (CA) strategy attempted in 215 patients (38.6%) with self-expandable TAVR devices (Evolut Pro/Pro+ and Acurate neo2).
Number of subjects: 557

Group type: COMPARATOR
Intervention: Moderate/severe CMA in patients without CA.
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: CA strategies used in self-expandable TAVR devices (ACN2 and EP).
Number of subjects: 557
Study: 39252600

Group type: EXPERIMENTAL
Intervention: Living in poverty
Number of subjects: 5833

Group type: EXPERIMENTAL
Intervention: Unhealthy alcohol use
Number of subjects: 5833

Group type: EXPERIMENTAL
Intervention: Heavy tobacco smoking
Number of subjects: 5833

Group type: EXPERIMENTAL
Intervention: Living with a stable partner
Number of subjects: 5833
Study: 39252617

Group type: EXPERIMENTAL
Intervention: PACMAN (Pre-operative triAge proCedure to streaMline elective surgicAl patieNts)
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: PACMAN
Number of subjects: 965

Group type: COMPARATOR
Intervention: Standard care (evaluation of standard care)
Number of subjects: 965
Study: 39252657

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (225 mg twice daily)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate
Number of subjects: 315

Group type: COMPARATOR
Intervention: 1.62% topical testosterone gel
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 315
Study: 39252725

Group type: EXPERIMENTAL
Intervention: Moderated hypofractionated online adaptive radiotherapy (MHRT with oART)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 0
Study: 39252861

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39252865

Group type: EXPERIMENTAL
Intervention: Adebrelimab (20 mg/kg, D1, Q3W) plus chemotherapy (EP/EC) followed by sequential thoracic radiotherapy (TRT)
Number of subjects: 67
Study: 39252867

Group type: EXPERIMENTAL
Intervention: Hexasodium fytate 7 mg/kg
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 39252988

Group type: EXPERIMENTAL
Intervention: Artificial intelligence method for indicating flap trimming
Number of subjects: 10

Group type: COMPARATOR
Intervention: Indocyanine green fluorescence angiography (ICGFA)
Number of subjects: 10
Study: 39253004

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Health Promotion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attachment-Based Compassion Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual treatments (workshops)
Number of subjects: 0
Study: 39253025

Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC) intervention, TBI Care, with weekly assessments and an average of 11 out of 12 sessions with a care manager (CM).
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC) intervention, TBI Care.
Number of subjects: 79